RUSSELL SMITH: Open Payments
NPI 1902497142 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,140 in 84 payments from 37 companies in 2025. Trend: 2023 $227 · 2024 $1,762 · 2025 $2,140
Food & beverage: $2,140
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $225 |
| AstraZeneca Pharmaceuticals LP | 7 | $178 |
| Daiichi Sankyo Inc. | 6 | $150 |
| Janssen Biotech, Inc. | 5 | $138 |
| Genentech USA, Inc. | 6 | $131 |
| Merck Sharp & Dohme LLC | 4 | $123 |
| GENZYME CORPORATION | 4 | $111 |
| Regeneron Healthcare Solutions, Inc. | 3 | $89 |
| PFIZER INC. | 3 | $82 |
| ABBVIE INC. | 3 | $81 |
Products named: Enhertu, KEYTRUDA, SCEMBLIX, LIBTAYO, Fabhalta, SARCLISA, Zoladex, VENCLEXTA.
Industry payments across GA — which companies pay providers there.
